GlassScriptPhysician profile
Priti Nath
NPI 1861789422
$7,286.45
in general payments reported to CMS, 2019-2025
34 companies · $4,892 in 2025
The $4,892 reported for 2025 was more than what 87% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $412 · 2024: $1,983 · 2025: $4,892.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,212 · Travel and Lodging: $1,043 · Education: $31.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,211.59 |
| Travel and Lodging | $1,043.35 |
| Education | $31.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,664.12 | 2023-2025 | Minimed 780g |
| Cequr Corporation | $669.73 | 2023-2025 | Cequr Simplicity |
| Insulet Corporation | $602.86 | 2024-2025 | Omnipod |
| Corcept Therapeutics | $587.09 | 2023-2025 | Korlym |
| Beta Bionics, INC. | $455.73 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amgen INC. | $304.63 | 2024-2025 | Tepezza, Evenity, Repatha |
| Novo Nordisk INC | $294.62 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $293.60 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $282.77 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $277.82 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $266.73 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $216.26 | 2023-2025 | Tymlos |
| Mannkind Corporation | $163.97 | 2023-2024 | Afrezza |
| Sanofi-Aventis U.S. LLC | $155.57 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $139.18 | 2025 | Isturisa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.71 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Dexcom, INC. | $95.49 | 2024-2025 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $87.82 | 2025 | Qutenza |
| Ascendis Pharma Endocrinology INC | $85.37 | 2025 | Yorvipath |
| Novartis Pharmaceuticals Corporation | $69.69 | 2024-2025 | |
| Pfizer INC. | $68.99 | 2023-2025 | |
| Abbvie INC. | $62.94 | 2024-2025 | |
| Ascensia Diabetes Care US INC. | $58.12 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $53.31 | 2023-2025 | Farxiga |
| Amneal Pharmaceuticals LLC | $28.88 | 2025 | Unithroid |
| Rhythm Pharmaceuticals, INC. | $27.29 | 2025 | Imcivree |
| Biogen, INC. | $27.20 | 2025 | Skyclarys |
| Alexion Pharmaceuticals, INC. | $26.01 | 2024 | Strensiq |
| Astellas Pharma US INC | $24.06 | 2024 | Veozah |
| Neurocrine Biosciences, INC. | $23.61 | 2025 | |
| Chiesi USA, INC. | $23.22 | 2025 | Mycapssa |
| Ibsa Pharma INC. | $15.90 | 2025 | Licart, Flector, Tirosint |
| Esperion Therapeutics, INC. | $15.64 | 2024 | Nexletol |
| Tolmar, INC. | $13.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priti Nath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.